TCO conjugates and methods for delivery of therapeutic agents

Patent metadata

Field	Value
Publication number	US-12257326-B2
Application number	US-202017018314-A
Country	US
Kind code	B2
Filing date	Sep 11, 2020
Priority date	Mar 14, 2014
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

First claim

What is claimed is:

1. A solid support composition comprising:
a biocompatible solid support;
at least one binding agent; and
a linker comprising from about 1 to about 10 linking atoms, covalently linking each binding agent to the biocompatible solid support,
wherein the binding agent and the linker together have the structure selected from the group consisting of:

2. The composition of claim 1 , wherein the solid support comprises a hydrogel.

3. The composition of claim 1 , wherein the solid support comprises alginate.

4. The composition of claim 1 , wherein the solid support comprises agarose.

5. The composition of claim 1 , wherein the binding agent and the linker together have the structure selected from the group consisting of:

6. The composition of claim 1 , wherein the composition has the structure selected from the group consisting of:

7. A method for selectively delivering an effective amount of a therapeutic or diagnostic agent to a first location of a targeted organ or tissue in a patient, comprising the steps of:
(a) implanting in the patient at the first location of the targeted organ or tissue a solid support composition comprising a biocompatible solid support, a first binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the biocompatible solid support; and
(b) administering to the patient a bioactive composition comprising a therapeutic or diagnostic agent, a second binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the therapeutic or diagnostic agent, wherein the first and second binding agents bind to one another upon contact,
wherein the therapeutic or diagnostic agent is released,
thereby selectively delivering the effective amount of the therapeutic or diagnostic agent to the first location of the targeted organ or tissue in the patient,
wherein the first and second binding agents are each selected from the group consisting of trans-cyclooctene and tetrazine such that one of the first and second binding agents is trans-cyclooctene and one of the first and second binding agents is tetrazine.

8. The method of claim 7 , wherein the first binding agent is trans-cyclooctene and the second binding agent is tetrazine.

9. The method of claim 7 , wherein the second binding agent is 1,2,4,5-tetrazine.

10. The method of claim 7 , wherein the solid support composition is:

11. The method of claim 7 , wherein
the solid support composition is:

 and
the bioactive composition is selected from the group consisting of:

wherein R is selected from the group consisting of the therapeutic agent and the diagnostic agent.

12. The method of claim 7 , wherein the targeted organ or tissue is bone.

13. The method of claim 7 , wherein the concentration of the therapeutic or diagnostic agent at the first location of the targeted organ or tissue is greater than the concentration elsewhere in the patient.

14. The method of claim 7 , wherein the therapeutic agent is vancomycin.

15. The composition of claim 1 , wherein the solid support is selected from a group consisting of a polysaccharide hydrogel, alginate, agarose, cellulose, hyaluronic acid, chitosan, chitin, chondroitin sulfate, heparin, polymer matrix, a metal, a ceramic, and a plastic, each of which may be optionally modified.

16. The composition of claim 15 , wherein the plastic is selected from the group consisting of polyphosphazenes, polyanhydrides, polyacetals, poly(ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, polyethers, and co-polymers thereof.

17. The composition of claim 1 , wherein the solid support comprises a carboxymethyl modification of hydroxyl or amino groups.

18. The composition of claim 1 , wherein the solid support is modified by esterification of carboxylic acids, conversion of alcohols to ethers or esters, or conversion of acids or amines to amides.

19. The composition of claim 1 , wherein the solid support comprises proteins and other poly(amino acids).

20. The composition of claim 19 , wherein the proteins and other poly(amino acids) are selected from the group consisting of collagen, gelatin, elastin and elastin-like polypeptides, albumin, fibrin, poly(gamma-glutamic acid), poly(L-lysine), poly(L-glutamic acid), and poly(aspartic acid).

Assignees

• Univ California
• Univ New York State Res Found

Inventors

• Mejia Oneto Jose Manuel
• Royzen Maksim

Classifications

• A61K49/0073

  semi-solid, gel, hydrogel, ointment · CPC title

• A61K49/0043

  Fluorescein, used in vivo · CPC title

• A61K51/1213

  Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature · CPC title

• A61K49/0052

  Small organic molecules (oligomers, polymers, dendrimers A61K49/0054) · CPC title

• A61K38/12

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title